Patents by Inventor Yufeng Hong

Yufeng Hong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Drug-Conjugates, Conjugation Methods, And Uses Thereof
    Publication number: 20210187119
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • Drug-conjugates, conjugation methods, and uses thereof
    Patent number: 10967071
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: April 6, 2021
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • Drug-Conjugates With a Targeting Molecule and Two Different Drugs
    Publication number: 20210017274
    Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 21, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski
  • Drug-conjugates with a targeting molecule and two different drugs
    Patent number: 10836821
    Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: November 17, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski
  • DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF
    Publication number: 20180243438
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: December 26, 2017
    Publication date: August 30, 2018
    Applicant: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • Drug-conjugates, conjugation methods, and uses thereof
    Patent number: 9981046
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: May 29, 2018
    Assignee: Concortis Biosystems, Corp., a wholly owned subsidiary of Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF
    Publication number: 20180085471
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Application
    Filed: August 17, 2017
    Publication date: March 29, 2018
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Drug-conjugates, conjugation methods, and uses thereof
    Patent number: 9884127
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: February 6, 2018
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • Drug-conjugates, conjugation methods, and uses thereof
    Patent number: 9801951
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 31, 2017
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Drug-Conjugates, Conjugation Methods, and Uses Thereof
    Publication number: 20160067350
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: May 14, 2013
    Publication date: March 10, 2016
    Applicant: Concortis Biosystems, Corp., a wholly owned subsidiary of Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Drug-Conjugates, Conjugation Methods, and Uses Thereof
    Publication number: 20150141646
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Applicant: Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc,
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS
    Publication number: 20150105540
    Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Applicant: Sorrento Therapeutics Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski
  • Drug-Conjugates, Conjugation Methods, and Uses Thereof
    Publication number: 20150105539
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: May 14, 2013
    Publication date: April 16, 2015
    Applicant: Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • 3-amido-pyrrolo[3,4-]pyrazole-5(1, 4,6) carbaldehyde derivatives
    Patent number: 8999981
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: April 7, 2015
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators
    Patent number: 8748412
    Abstract: Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metabolic disorder.
    Type: Grant
    Filed: February 2, 2011
    Date of Patent: June 10, 2014
    Assignee: Argusina Bioscience Inc.
    Inventors: Jiayu Liao, Yufeng Hong, Yong Wang, Thomas W. Von Geldern, Kanyin E. Zhang
  • Pyrrolopyrazoles, potent kinase inhibitors
    Patent number: 8530652
    Abstract: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 10, 2013
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Junhu Zhang, Chuangxing Guo, Djamal Bouzida, Liming Dong, Haitao Li, Joseph Timothy Marakovits, Anle Yang, Yufeng Hong
  • PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS
    Publication number: 20120264751
    Abstract: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    Type: Application
    Filed: October 6, 2011
    Publication date: October 18, 2012
    Inventors: Junhu ZHANG, Chuangxing Guo, Djamal Bouzida, Liming Dong, Haitao Li, Joseph Timothy Marakovits, Anle Yang, Yufeng Hong
  • NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES
    Publication number: 20120108588
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 3, 2012
    Applicant: Pfizer, Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives
    Patent number: 8114871
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: February 14, 2012
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS
    Publication number: 20120004198
    Abstract: Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metabolic disorder.
    Type: Application
    Filed: February 2, 2011
    Publication date: January 5, 2012
    Applicant: ARGUSINA INC.
    Inventors: Jiayu LIAO, Yufeng Hong, Yong Wang, Thomas W. Von Geldern, Kanyin E. Zhang